Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 17/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 11/20 | 1.00 |
| ▸ | KDM1A | O60341 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4959537 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2KDM1A | |
| SCHEMBL4959526 | 1.00 | GRIA2 (1.00) | GRIA2KCNH2KDM1A | |
| SCHEMBL5186675 | 0.94 | GRIA2 (0.88) | GRIA2KCNH2KDM1A | |
| SCHEMBL5186679 | 0.94 | GRIA2 (0.88) | GRIA2KCNH2KDM1A | |
| SCHEMBL5186693 | 0.94 | GRIA2 (0.88) | GRIA2KCNH2KDM1A | |
| SCHEMBL5186688 | 0.94 | GRIA2 (0.88) | GRIA2KCNH2KDM1A | |
| SCHEMBL4960143 | 0.91 | GRIA2 (0.84) | GRIA2KCNH2KDM1A | |
| SCHEMBL5446020 | 0.91 | GRIA2 (0.84) | GRIA2KCNH2KDM1A | |
| SCHEMBL5446026 | 0.91 | GRIA2 (0.84) | GRIA2KCNH2KDM1A | |
| SCHEMBL4957216 | 0.89 | GRIA2 (0.80) | GRIA2KCNH2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | claimed |
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270471-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRM3, GLRA3, GLRA1 | GRIA2 34/4885KCNH2 562/4885KDM1A 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.